BRPI1008014A2 - domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro - Google Patents

domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro

Info

Publication number
BRPI1008014A2
BRPI1008014A2 BRPI1008014A BRPI1008014A BRPI1008014A2 BR PI1008014 A2 BRPI1008014 A2 BR PI1008014A2 BR PI1008014 A BRPI1008014 A BR PI1008014A BR PI1008014 A BRPI1008014 A BR PI1008014A BR PI1008014 A2 BRPI1008014 A2 BR PI1008014A2
Authority
BR
Brazil
Prior art keywords
tnfr1
multispecific ligand
tnf
polypeptide
vector
Prior art date
Application number
BRPI1008014A
Other languages
English (en)
Portuguese (pt)
Inventor
Adrianns Allart Stoop
Armin Sepp
Carolyn Enever
Haiqun Liu
Oliver Schon
Stephen Duffield
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI1008014A2 publication Critical patent/BRPI1008014A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI1008014A 2009-02-19 2010-02-17 domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro BRPI1008014A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15374609P 2009-02-19 2009-02-19
US24119809P 2009-09-10 2009-09-10
PCT/EP2010/052005 WO2010094720A2 (en) 2009-02-19 2010-02-17 Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists

Publications (1)

Publication Number Publication Date
BRPI1008014A2 true BRPI1008014A2 (pt) 2016-10-04

Family

ID=42136168

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008014A BRPI1008014A2 (pt) 2009-02-19 2010-02-17 domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro

Country Status (14)

Country Link
US (1) US20110301335A1 (enExample)
EP (1) EP2398827A2 (enExample)
JP (2) JP2012517818A (enExample)
KR (1) KR20110119806A (enExample)
CN (1) CN102405236A (enExample)
AU (1) AU2010215479B2 (enExample)
BR (1) BRPI1008014A2 (enExample)
CA (1) CA2750477A1 (enExample)
EA (1) EA022925B1 (enExample)
IL (1) IL214648A0 (enExample)
MX (1) MX2011008799A (enExample)
SG (1) SG173173A1 (enExample)
WO (1) WO2010094720A2 (enExample)
ZA (1) ZA201105627B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028822B2 (en) * 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
SG173489A1 (en) * 2009-02-19 2011-09-29 Glaxo Group Ltd Improved anti-serum albumin binding variants
WO2011008814A2 (en) * 2009-07-14 2011-01-20 Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation Multiplexed measurement of exogenous and endogenous dna
CA2768460A1 (en) * 2009-07-16 2011-01-20 Glaxo Group Limited Antagonists, uses & methods for partially inhibiting tnfr1
ES2552177T3 (es) * 2009-10-27 2015-11-26 Glaxo Group Limited Polipéptidos anti-TNFR1 estables, dominios variables de anticuerpos y antagonistas
JP2013529080A (ja) * 2010-05-20 2013-07-18 グラクソ グループ リミテッド 改良された抗血清アルブミン結合変異体
WO2012035141A1 (en) 2010-09-16 2012-03-22 Baliopharm Ag Anti-hutnfr1 antibody
US20140112929A1 (en) * 2011-06-17 2014-04-24 Glaxo Group Limited Tumour necrosis factor receptor 1 antagonists
WO2015104322A1 (en) 2014-01-09 2015-07-16 Glaxosmithkline Intellectual Property Development Limited Treatment of inflammatory diseases with non-competitive tnfr1 antagonists
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
WO2016094309A1 (en) * 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
NO2768984T3 (enExample) * 2015-11-12 2018-06-09
CN107043413A (zh) * 2016-02-05 2017-08-15 华中农业大学 一种肺结核相关的尿液生物标志蛋白及其应用
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2020158858A1 (ja) * 2019-01-31 2020-08-06 積水メディカル株式会社 生物学的試料中の遊離ａｉｍの免疫学的分析方法及び対象におけるｎａｓｈの検出方法
WO2020172218A1 (en) 2019-02-21 2020-08-27 Enosi Life Sciences Corp. Antibodies and enonomers
IL300930A (en) 2020-08-27 2023-04-01 Enosi Therapeutics Corp Methods and compositions for the treatment of autoimmune diseases and cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2025021184A1 (zh) * 2023-07-27 2025-01-30 上海复宏汉霖生物医药有限公司 编码尿酸氧化酶的多核苷酸及其相关组合物和方法
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
EP2258846A3 (en) 1997-07-07 2012-03-21 Medical Research Council A method for increasing the concentration of a nucleic acid molecule
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CA2399388A1 (en) 2000-02-11 2001-08-16 Michael J. Lenardo Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
ATE477280T1 (de) 2001-06-28 2010-08-15 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
WO2005077042A2 (en) 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Albumin fusion proteins
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
CA2492092A1 (en) 2002-06-28 2004-01-08 Greg Winter Immunoglobin single variant antigen-binding domains and dual-specific constructs
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
CA2505325C (en) 2002-11-08 2014-02-25 Ablynx N.V. Stabilized single domain antibodies
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EP2357237A1 (en) 2003-05-14 2011-08-17 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
PT1639011E (pt) 2003-06-30 2009-01-20 Domantis Ltd Anticorpos (dab) de domínio único peguilados
PL1737962T3 (pl) 2004-03-24 2011-02-28 Domantis Ltd Uniwersalny lider GAS1
GB0418651D0 (en) 2004-08-20 2004-09-22 Medical Res Council Method
CN101084014A (zh) * 2004-10-08 2007-12-05 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
EA200801170A1 (ru) * 2005-12-01 2008-12-30 Домантис Лимитед Форматы неконкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
AU2006323412A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EA200901494A1 (ru) * 2007-06-06 2010-06-30 Домантис Лимитед Способы селекции протеазоустойчивых полипептидов
US7868885B2 (en) 2007-06-22 2011-01-11 Microsoft Corporation Direct manipulation of subdivision surfaces using a graphics processing unit
CN102574914A (zh) * 2009-07-16 2012-07-11 葛兰素集团有限公司 改进的抗血清清蛋白结合性单可变区
CA2768460A1 (en) * 2009-07-16 2011-01-20 Glaxo Group Limited Antagonists, uses & methods for partially inhibiting tnfr1
ES2552177T3 (es) * 2009-10-27 2015-11-26 Glaxo Group Limited Polipéptidos anti-TNFR1 estables, dominios variables de anticuerpos y antagonistas

Also Published As

Publication number Publication date
US20110301335A1 (en) 2011-12-08
CN102405236A (zh) 2012-04-04
WO2010094720A3 (en) 2011-01-13
CA2750477A1 (en) 2010-08-26
IL214648A0 (en) 2011-09-27
AU2010215479A1 (en) 2011-08-25
KR20110119806A (ko) 2011-11-02
WO2010094720A2 (en) 2010-08-26
JP2016007218A (ja) 2016-01-18
ZA201105627B (en) 2013-01-30
MX2011008799A (es) 2011-09-27
EP2398827A2 (en) 2011-12-28
JP2012517818A (ja) 2012-08-09
SG173173A1 (en) 2011-08-29
AU2010215479B2 (en) 2015-01-22
EA022925B1 (ru) 2016-03-31
EA201190116A1 (ru) 2012-06-29

Similar Documents

Publication Publication Date Title
BRPI1008014A2 (pt) domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro
BR112012025101A2 (pt) compostos antagonistas seletivos de receptor nk-3, composição farmacêutica e métodos para uso em distúrbios mediados por receptores nk-3
BR112013008255A2 (pt) anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo
BR112014003679A2 (pt) domínio variável de imunoglobina único, composição farmacêutica, uso de um domínio variável de imonuglobina único, método de tratamento ou prevenção de pelo menos uma doença ou distúrbio ou condição, formulação, dispositivo de dispensação, ácido nucleico isaldo ou recombinante, vetor, célula hospedeira, e, método para produzir um polipeptídeo
BRPI1008060A2 (pt) Agonistas e antagonistas do receptor s1p5, e métodos de uso do mesmo.
BRPI1006134A2 (pt) anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada.
IL221620A (en) Antagonist antibodies against the interleukin receptor 7 and methods for their use
BR112013008821A2 (pt) aparelho de determinação de propriedades para determinar propriedades de objetos, método de determinação de propriedades para determinar propriedades de objetos e programa de computador de determinação de propriedades para determinar propriedade de objeto
BR112014004168A2 (pt) anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
PT2547679E (pt) Derivados de 2,3-di-hidro-1h-indeno-1-il-2,7-diazaspiro[3.6]nonano e sua utilização como antagonistas ou agonistas inversos do receptor de grelina
BR112012016268A2 (pt) método para realizar relatórios de estado de memória temporária, sistema para realizar relatórios de estado de memória temporária e equipamento de usuário para realizar relatórios de estado de memória temporária
BRPI1013807A2 (pt) composição, uso de uma composição, antagonista, sequência de polinucleotídeo, célula hospedeira recombinante transformada ou transfectada, método para a produção de uma composição, método para prevenir ou tratar um paciente, molécula de ligação de antígeno de marcação dual, e, proteína de ligação de antígeno.
BR112014016076A8 (pt) peptídeo, vetor, contrução de peptídeo quimérico, ácido nucleico e uso dos mesmos e composição farmacêutica
BR112013001571A2 (pt) composto, composição farmacêutica, uso e método de prevenção ou tratamento de uma condição associada com a função do receptor gpr40
BR112013004782A2 (pt) sistema de resistência de fluxo variável para utilização em um poço subterrâneo
EP2417748A4 (en) SYSTEMS, METHODS AND APPARATUS FOR CONTINUOUS TRANSMISSION OF MULTIMEDIA FILES
BR112013004359A2 (pt) fluido de furo de poço, e método para distribuir material particulado abaixo do terreno
BRPI0813216A2 (pt) Inibidores de proteínas cinases e métodos para usá-los.
BRPI0919377A2 (pt) anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
LT2766395T (lt) Antikūno polipeptidai, kaip cd40l antagonistai
BR112012030515A2 (pt) sistema para determinar o teor de asfalteno de óleo bruto, e método para determinar o teor de asfalteno de óleo bruto.
BR112012026174A2 (pt) anticorpo isolado, ácido nucleico isolado, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, doença ou disfunção, uso do anticorpo, método de tratamento, de determinação e de separação
BRPI1009419A2 (pt) mistura asfaltica, e metodo de pavimentacao
LT4152004T (lt) Tyrimas, skirtas antikūnams prieš jc virusą nustatyti
BR112012030099A2 (pt) sistema de emulsificação no campo, e método para misturar no campo um fluido aquoso e um fluido de hidrocarboneto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B15K Others concerning applications: alteration of classification

Ipc: C07K 16/28 (2006.01), C07K 16/18 (2006.01), A61K 3

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2449 DE 12-12-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]